Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 3;25(1):290.
doi: 10.1186/s12882-024-03727-3.

Pathogenic microorganism DNA high-throughput genetic sequencing to diagnose peritoneal dialysis-associated peritonitis due to Mycobacterium tuberculosis infection

Rui-Feng Xu  1 , Wu-Niri Gao  1 , Ta-la Hu  1 , Xi-Feng Wang  2 , Jian-Rong Zhao  1 , Yan Meng  3
Affiliations
Case Reports

Pathogenic microorganism DNA high-throughput genetic sequencing to diagnose peritoneal dialysis-associated peritonitis due to Mycobacterium tuberculosis infection

Rui-Feng Xu et al. BMC Nephrol. .

Abstract

Peritoneal dialysis-associated peritonitis is a serious complication of peritoneal dialysis, and the prevention and treatment of this condition are important for improving the long-term survival and quality of life of patients. However, peritoneal dialysis-associated peritonitis due to Mycobacterium tuberculosis infection is relatively rare and not easily diagnosed. Here, we present a case of peritoneal dialysis-associated peritonitis caused by Mycobacterium tuberculosis identified by pathogenic microbial DNA high-throughput genetic sequencing. This case demonstrates that pathogenic microbial DNA high-throughput genetic sequencing could be used to improve the detection rate of pathogenic microorganisms in patients with complex conditions, thereby allowing for earlier initiation of treatment.

Keywords: Mycobacterium tuberculosis; Pathogenic microorganism DNA high-throughput genetic sequencing (PMseq-DNA); Peritoneal dialysis; Peritoneal dialysis-associated peritonitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Changes in the dialysis effluent cell count, CRP level, and medication used during treatment. IP, intraperitoneal; IV, intravenous injection; PO, taken orally; CRP, C-reactive protein
See this image and copyright information in PMC

References

    1. Changlin Mei XG. Chaoyang Ye: practical Dialysis Handbook. Beijing: People’s Medical Publishing House; 2017.
    1. Szeto C-C, Li PK-T. Peritoneal Dialysis–Associated Peritonitis. Clin J Am Soc Nephrol. 2019;14(7):1100–5. 10.2215/CJN.14631218 - DOI - PMC - PubMed
    1. Thomson BKA, Vaughan S, Momciu B. Mycobacterium tuberculosis peritonitis in peritoneal dialysis patients: a scoping review. Nephrology. 2021;27(2):133–44. 10.1111/nep.13997 - DOI - PubMed
    1. Sanai FM, Bzeizi KI. Systematic review: tuberculous peritonitis – presenting features, diagnostic strategies and treatment. Aliment Pharmacol Ther. 2005;22(8):685–700. 10.1111/j.1365-2036.2005.02645.x - DOI - PubMed
    1. Liu R, Li J, Tan Y, Shang Y, Li Y, Su B, Shu W, Pang Y, Gao M, Ma L. Multicenter evaluation of the acid-fast bacillus smear, mycobacterial culture, Xpert MTB/RIF assay, and adenosine deaminase for the diagnosis of tuberculous peritonitis in China. Int J Infect Dis. 2020;90:119–24. 10.1016/j.ijid.2019.10.036 - DOI - PubMed

Publication types

Grants and funding

LinkOut - more resources